Labelys organized a new buy-out to welcome Florac, Cerea, and Unigrains as new shareholders. The management team maintains a significant minority stake (~40% slightly diluted). The primary objective of this EUR200M equity injection is to finance a new wave of acquisitions across Europe. The financing package includes a senior debt and a Tranche C (private debt), with a leverage kept below 4x EBITDA, providing the group with a robust M&A "war chest" to reach EUR350M+ in revenue by 2028.

The transaction values LABELYS at an EV/Revenue multiple of LOGIN.

This transaction is part of the Industry & Manufacturing industry, which currently tracks an average EBITDA multiple of 10.2x since the beginning of 2026, 2.1% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.